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Background: The multidisciplinary team (MDT) meeting has become the hallmark for cancer 
care in the UK. While standardizing care through adherence to guidelines, the MDT process 
can make the decision-making process somewhat remote from the patient perspective. The 
Cholangiocarcinoma Charity (AMMF) is the UK’s only cholangiocarcinoma charity and is at 
the forefront of patient empowerment for those with this condition and for their families. It 
provides much needed support not only via personal contact but also through its website and 
on the social media platforms, Facebook and Twitter. 
Methods: AMMF conducted a survey of patient attitudes to and experience of the MDT pro-
cess through a simple questionnaire posted on Facebook in 2014. We report the results of the 
responses received, which we believe are worthy of further thought. 
Findings: In the main, while treatment decisions are not queried, there is distress at the lack of 
involvement, the lack of representation, the lack of communication and at not knowing who to 
approach for answers to questions. 
Conclusion: This snapshot, although small, provides some insight to clinicians not to forget 
the constituency they serve, as communication is all important.
Keywords: cholangiocarcinoma, multidisciplinary team meeting, management, patient 
perspectives
Introduction
The multidisciplinary team (MDT) meeting has become a familiar and mandatory part 
of the care pathway for patients with cancer or suspected cancer in the modern age.1 
There has been much written about the efficiency of thought from the professional 
perspective with the opportunity for physicians, oncologists, radiotherapists, surgeons, 
palliative care physicians, radiologists and histopathologists to be able to meet on a 
weekly basis to guide and monitor a joint approach to the care of individual patients 
within a hospital trust or network of hospitals at a local or regional level.2 Furthermore, 
much has been written about the health economics of such an approach to the point that 
it seems the supremacy of the MDT or its wisdom is no longer questioned.3,4 While a 
well-functioning MDT is undoubtedly a benchmark for good quality care, in reality,5–7 
many MDTs in the UK are hard pressed with a tsunami of work to get through and little 
time to discuss all cases properly in the hour or so allotted, often at the beginning of 
the day, before “real work” begins. In addition, the hard fact is that while each patient 
discussed should have a clinical advocate (who knows them) present at the MDT, 
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often this is not the case in the UK with decisions made by a 
well-meaning team who are usually bound by guidelines and 
who make decisions, based on radiological and histological 
evidence, in the absence of direct patient contact. As this 
process is driven by a panel of experts, often quite remote 
from the patients and their families, it has the potential to give 
rise to weaknesses in approach to patient communication, one 
which has the potential not only to cause emotional distress 
and anxiety to those undergoing diagnosis and treatment, but 
which threatens to exclude the patient as a “conscious” and 
involved participant in their own care and recovery.
In the spirit of appraisal, it is worth considering what 
patients think about the MDT process and what it means to 
them. Cholangiocarcinoma or bile duct cancer is becoming 
steadily more common, and it is a particularly cruel disease 
in that it presents rapidly and usually too late for meaning-
ful intervention, giving patients and their families little time 
to adjust to a condition, where incidence and mortality are 
almost the same.8 The Cholangiocarcinoma Charity (AMMF) 
is the UK’s only dedicated cholangiocarcinoma charity, and 
it supports patients and their families coming to terms with 
difficult diagnoses, in addition to supporting medical research 
on cholangiocarcinoma (www.ammf.org.uk). 
The charity is active on the social media platforms, Face-
book and Twitter, to keep its followers informed of clinical 
and research developments in the field. As Chairman of 
AMMF, Helen Morement was approached to speak on patient 
attitudes toward the MDT and their experiences at a national 
forum in Liverpool, UK. Before doing so, she commissioned 
a questionnaire using the AMMF Facebook page to ascertain 
the views of patients and their families regarding the MDT 
process for cholangiocarcinoma. We report the results of the 
responses to this Facebook questionnaire. 
Although this descriptive approach is unusual in that we 
report the results of a social media survey where the respon-
dents are self-selected, and it therefore lacks scientific validity 
in terms of standardization and statistical methodology. The 
patient responses are reported without subjective editing, 
and in the spirit of 360 degree feedback, they are worthy of 
further thought. 
Methods
Prior to speaking on the subject, “MDT – The Patients’ 
Perspective” at the European Society of Surgical Oncology 
(ESSO) and the British Association for Surgical Oncology 
(BASO) MDT Course on November 1, 2014, the AMMF’s 
Chairman Helen Morement used the charity’s Facebook 
page to invite supporters to supply answers, comments and 
thoughts, either openly on the public site or privately by email 
on the following series of questions:
1. If you, or someone you are close to, has been diagnosed 
with cholangiocarcinoma, were you/they told that your/
their treatment would be discussed at an MDT meeting?
2. If you were told about an MDT meeting, did you know 
what this meant and did you understand what would be 
happening?
3. Did you have an opportunity to ask questions about this, 
and were they fully answered to your satisfaction?
4. How were the decisions on treatment options reported 
back to you?
5. Did you have an opportunity to ask questions about this?
As this was an entirely empirical exchange on a busy 
social media site, run by the lay public for the lay public, 
and aimed at promoting patient welfare, research ethics to 
carry out the questionnaire was considered unnecessary by 
the AMMF Charity Board of Trustees. We present completely 
anonymized data from the online survey. However, the major-
ity of respondents, whether commenting openly on Facebook 
or via email, agreed to their responses and to their names 
being shared publicly. 
All participants included in this report were emailed and 
gave their subsequent permission for the publication of the 
collective, anonymized findings for educational, research and 
health care quality improvement purposes. Their information 
provided the detail for the oral presentation in Liverpool, 
and the responses are shown in full in the “Results” section. 
The fully anonymized responses to the questionnaire doc-
ument were circulated as a printed handout to all the attendees 
at the ESSO-BASO Cancer MDT Course in November 2014 
with the respondents’ prior agreement. 
Results
The following are the unedited, empirical responses to the 
questionnaire posted on the AMMF Facebook page:
Respondent 1
We were told on the day that the diagnosis was given to us 
that my father would be discussed by an MDT at the regional 
teaching hospital and that numerous professionals attended 
these meetings.
The clinical nurse at district general hospital said she had 
rushed through our appointment at which the doctor told us 
it was cancer, so my father’s case could be discussed at that 
Wednesday’s meeting, otherwise we would have had to wait 
until the following Wednesday for his case to be discussed. 
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We were not told we could ask questions. We did not get much 
feedback apart from being told that my dad was not able to be 
operated on, but that chemotherapy was an option to control, 
not to cure it. I suppose I would have liked the chance to speak 
to some of the people at the meeting and maybe ask further 
questions, but at least we were told this much.
Of course I completely understand that we are not 
allowed to attend the meetings, nothing would ever get 
decided. I agree that more could be done to make us feel 
fully involved. However, I appreciate that with the number 
of cancer patients ever increasing then there has to be a limit 
to that involvement.
I suppose I am trying to understand from the medical 
profession’s point of view as well, but that is not my problem 
to worry about when I have enough to deal with, and I have 
never felt I could just pick up the phone or email someone 
about this, because no one has told us this is something we 
can do. If we had access to a patient advocate that could make 
this whole traumatic experience a little easier.
Respondent 2
I recall being told after diagnosis that my case was to be 
discussed at a meeting in another hospital and that this was 
attended by a range of medical specialists from a wide area.
MDTs exist in other professional areas and I had attended 
many over the years. Some of these events had been very 
positive and some less so, dependent on those attending 
and particularly the “chair or lead professional”. Decisions 
taken by committee can sometimes involve compromise. I do 
remember thinking I hope the key individuals are all actually 
there. I also remember that this was an unusual approach and 
that this thickened the fog of first, a cancer diagnosis and 
second, one that was complex.
The effect on the patient of the apparent delay in agreeing 
a way forward, even for a day or a weekend, should never be 
underestimated. This sends a very mixed message. The lack 
of the usual pathway of one individual physician or surgeon 
explaining what procedure they intended to carry out was 
unsettling. Would literature on what the MDT constitutes 
be of help? I am not sure for me, but for those around me, 
I think it would. 
Respondent 3
We have been told on numerous occasions about my hus-
band’s case being discussed at the MDT meetings, which 
have mainly been reported back to us via the oncologist 
either by telephone or at our next clinic appointment, which 
caused inevitable delay.
Respondent 4
Having to wait for an MDT meeting can be frustrating, but it 
is necessary to have all the specialists together at once. As a 
nurse, I fully understood what the MDT was and what would 
be discussed, but it was frustrating that I had to constantly 
explain the medical terminology to my mother and the rest 
of the family. I often felt medical and nursing staff spoke to 
me rather than my mother, who was the patient.
The MDT decisions on treatment options were discussed 
and we were given time to ask questions. In fact, the doctor 
explained things clearly and used appropriate sketches to 
explain why and allowed my mother to take them home. When 
my mother had her chemotherapy regime explained, it was 
also written down for her. My mother’s case was discussed 
in numerous MDTs and we were always aware when these 
were taking place and why. The outcomes were discussed 
and on more than one occasion the doctor also rang me (at 
my mother’s request) to inform me.
Respondent 5
My mother had her case dealt with by an MDT and although 
we were grateful that such expertise was “on the team”, 
I recall feeling immense frustration that their weekly or even 
fortnightly meetings were so rigidly timed. For example, there 
could be an MDT meeting on a Wednesday afternoon, but 
if my mother had a scan on a Thursday morning she could 
have to wait up to 2 weeks for the results to be discussed.
I recall several calls to the hospital begging staff to run 
scan results down to the appropriate secretary, so that they 
could be included in that afternoon’s discussion. For all can-
cers, and specifically for aggressive, time-critical cancers like 
cholangiocarcinoma, I wondered why there was not a better 
solution to this. Two weeks could mean all the difference. 
Technology has surely evolved?
If I were going to add another point about the MDT, it 
would be nice to understand how and why decisions had been 
reached and to receive feedback.
Respondent 6
At the time of my husband’s first operation, there was no 
mention of MDT, because it was originally thought he had 
pancreatitis but, 2 weeks later we got the cholangiocarcinoma 
diagnosis as a result of the histology report. We were then 
told that there would be an MDT meeting the next Tuesday, 
a weekly event, involving, among others, the liver surgeon, 
who had performed the operation, and the oncologist and the 
next steps would be discussed. As my husband was still in 
the high dependency unit (HDU) due to complications from 
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post-operative methicillin-resistant Staphylococcus aureus 
(MRSA), the outcome of the meeting was discussed with us 
in the ward with plenty of chances to ask questions.
A year later when the cancer had spread to the duodenum, 
it was very different. There was an MDT meeting, but he 
was in a different ward and we had great difficulty getting 
any information. Indeed, the impression we got was that the 
professionals could not agree on next steps. Perhaps, the 
decision was more difficult to make, I do not know, but it was 
upsetting as we felt we were being kept in the dark.
My husband would never make a fuss, but I did the “fuss 
bit” for both of us, desperate for information. Two extreme 
opposite experiences, and I know which we preferred. It was 
so much better first time round to feel involved in the post-
MDT deliberations and have the opportunity to ask questions
Respondent 7
My parents and I were told by our local district general hos-
pital that the regional teaching hospital team had discussed 
and diagnosed my father’s cancer at an MDT. They then 
transferred my father to the regional teaching hospital for 
his stent procedure. Our local district general hospital had 
told us my father had a few months to live, but the regional 
teaching hospital offered chemotherapy and disagreed with 
the prognosis. We felt that there were mixed messages com-
ing from the MDT.
Six months later, my father’s case was discussed again 
at an MDT and it was decided nothing could be done. This 
news was broken to my father by the Macmillan nurse and 
he never saw the consultant again. Both times we were told 
after the MDTs and did not have a chance to put our ques-
tions forward. I often had to try to telephone or even email 
them to ask questions and get answers.
Respondent 8
I knew what an MDT was, but it has never been mentioned 
to me. My first experience was in France, while my second 
experience was at a district general hospital in the UK. Once 
it had been discovered that I had tumor recurrence at the MDT 
review, my oncologist simply told me that if I thought I had 
a tough time last time, it was nothing compared to what will 
happen. She told me I had 18–21 months to live (this was in 
July 2013), then told me to have a cup of coffee before driving 
the 45-minute journey home. I was on my own. There was 
no discussion at all regarding any treatment.
My third experience was at a regional teaching hospital. 
The oncologist there was excellent at explaining what and 
when things were going to happen. He did not mention an 
MDT specifically, but I certainly got the impression that my 
case had been discussed with others. He explained that I was 
to have chemotherapy and referred me to another teaching 
hospital for treatment.
My fourth experience was at the next teaching hospital. 
My oncologist explained every part of my treatment and, 
upon asking, explained why radiotherapy and surgery were 
not options in my case. I was happy with the decisions made 
and again felt my case had been discussed although there was 
never a mention of an MDT.
My only comment is that although I appreciate it would 
not be appropriate for a patient to attend an MDT, I think it 
would be helpful for members of the MDT to meet the patient 
for them to assess strength of character, and attitude, which 
could have an impact on decisions made. It could also be 
of benefit to the patient to gain confidence in the decision-
making process.
Respondent 9
I can honestly say I was told nothing. I went to see a liver 
consultant at the hospital. I was taken into a room full of 
people. I had no idea who they were. A consultant introduced 
himself and told me I needed a major operation as I had a 
tumor on my liver that needed to be removed. He said you 
have us baffled – there is no cancer showing in your body, 
but you need a major operation. MDT was never mentioned. 
I can recall being so confused that I cancelled the opera-
tion because of lack of knowledge. It was only when I was 
appointed a new consultant that I was invited to his clinic 
to ask questions and fully discuss my options and be told 
exactly what to expect.
Respondent 10
We were told very early on that my sister’s case would be 
discussed with an MDT. I am not sure that the word “MDT” 
was used but she knew that every Friday afternoon a meeting 
was held with surgeons, oncologists, etc. As a nurse, I knew 
what an MDT was, so I could explain it.
Whenever a decision was being made at the MDT, my 
sister knew she was being discussed at the meeting and 
was told by her surgeon that he would ring her after. This 
was always after 5 pm on a Friday afternoon. He always 
phoned and I have to say the news she was given was always 
extremely hard to hear. It had to be done by phone, because 
of the distance involved and the rapidity of decisions being 
made and plans put in place. She was always allowed to ask 
questions but often more cropped up after the phone call and 
she had to wait until Monday to contact a professional. That 
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is no-one’s fault and not a criticism but maybe a Friday 3 
pm MDT meeting is not the ideal time if you are delivering 
difficult news.
Respondent 11
I had an MDT before my surgery and took the advice that 
any delay would cause further problems down the recovery 
road. I had a diagnosis to operation (Whipple’s procedure) 
in two weeks. I believe that saved my life.
Discussion
This small snapshot of responses made on social media and 
by email, giving the experiences and thoughts of cholangio-
carcinoma patients and their families following the Facebook 
questionnaire conducted by AMMF on the perception of the 
MDT, is worthy of further reflection, although we acknowl-
edge that the survey was not designed to be representative 
of all experience and is entirely subjective and nonscientific. 
Although, in general, treatment decisions are not queried, 
there is respondent distress at the lack of involvement, the 
lack of representation, the lack of communication, and at not 
knowing who to approach for answers to questions. 
While our methodologies may be criticized for being 
unrepresentative, the concerns raised by the patient respon-
dents have been recurring themes at national public informa-
tion fora organized by the AMMF over the past couple of 
years across the UK. 
There does genuinely seem to be confusion among 
 cholangiocarcinoma patients and their families over the 
decision-making process used at MDT meetings and anxiety 
over whether anyone is present who might know the patient 
and act as their advocate, particularly if the MDT meeting is 
taking place at a different hospital from where care is being 
given. However, the two overwhelming issues seem to be: 
first, the perception that the MDT process may lengthen 
the time to a decision on the patient management pathway, 
particularly if the MDT convenes less frequently than every 
week and second, that communication between the MDT 
and the patient is often poor, with the MDT being seen as a 
remote body who sit in mysterious, secret conclaves, a bit like 
Catholic Cardinals electing a new Pope! With the emphasis 
on streamlining procedures and improving cost-effectiveness 
of cancer care, the MDT meeting has been championed as 
the guardian of quality and the champion of standardization 
of care according to national guidelines.4 It should also be 
borne in mind from the health care management point of view 
that in the context of cholangiocarcinoma and many other 
cancers, diagnosis is often difficult and the MDT framework 
provides the clinician with the framework for a consensus 
on diagnosis. However, it is certainly the case that deper-
sonalization can set in with patients with their lives at stake, 
being treated as numbered cases who are dealt with quickly 
and often dispassionately. Furthermore, if the responsible 
consultant is not present at the meeting, the communication 
of decisions can be delayed and outcomes can be conveyed 
in less than ideal circumstances.
Conclusion
This social media survey led by the lay public for the lay 
public is nonscientific in its methodology and serves only to 
alert the medical profession to potential problems in the MDT 
process. Furthermore, what has been reported for cholangio-
carcinoma, a rare cancer in the UK, cannot be extrapolated 
to all MDTs for every cancer, where more favorable patient 
experiences have been reported. 9–12 
Nevertheless, in an era of patient-centered care, we would 
suggest that clinicians who have personal knowledge of their 
patient, their character and attitude, always attend MDTs to 
act as their advocates, as very often decisions can be made on 
following rigid guidelines without knowledge of biological 
fitness or patient wishes. We would also suggest that in an 
age where efficiency is the aesthetic goal, but where there is 
an ever busier clinical load, time is made to impart decisions 
with compassion and an opportunity to ask questions. While 
this is done well in most cases, what seem to be basic human 
rights to the lay public are sometimes forgotten in the rush 
to see the next patient. 
While this may be understandable in terms of the pres-
sures of workload on medical professionals, it is also essential 
to consider the subjectivity of the patient as a vital element of 
the treatment process. This is not only from the perspective of 
basic human rights, agency and dignity but also in relation to 
the very practical concerns of active patient participation in 
their own health care agenda and the benefits of this participa-
tion to all those concerned. An alternative but perhaps more 
radical approach to patient participation is to have patients 
and their families present at MDT meetings.9 The possibil-
ity of patients taking part in the MDT is controversial, but 
it is something that many would wish for in a more patient-
centered health care system. Such approaches need to be 
discussed, but are not without the bounds of future possibility.
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